New research game changer
OpenSAFELY
https://opensafely.org
New secure analytics platform
Electronic health records in the NHS
Created to deliver urgent results during the COVID-19 emergency
Analyses across more than 24 million patients
Full pseudonymised primary care NHS records
More to follow shortly
Open for security review
Scientific review
Secure environments
Trusted analysts
Large scale computation
Near real-time
Analyses in just five weeks from project start.
More accuracy than any previous analyses by an order of magnitude
Big data
Primary care data
Sufficient statistical power
Associations with specific medications and medical conditions
Early during the pandemic
Save lives by modifying patient, clinician, and population behaviour
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Lancet, 5th November, MRC
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30378-7/fulltext
Hydroxychloroquine
Pre¬exposure (as opposed to post¬exposure) prophylactic
Inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro
No evidence of reduced mortality when treating patients with COVID-19
Methods
Observational
Population-based cohort study
Approximately 40% of the general population in England
Association between ongoing use before COVID-19
Compared with non-users of hydroxychloroquine
Risk of COVID-19 mortality
People with rheumatoid arthritis or systemic lupus erythematosus
n = 194, 637 with rheumatoid arthritis or systemic lupus erythematosus
n = 30, 569 received two or more prescriptions of hydroxychloroquine
March 1 and July 13, 2020
547 deaths
Users (n= 30,569)
70 deaths
IFR = 0.23%
Non – users (n = 164,068)
IFR = 0.22%
An absolute difference of 0·008%
Accounting for age, sex, ethnicity, use of other immunosuppressive drugs, and geographical
region
No association with COVID-19 mortality was observed
If you would like to donate to this educational project, please use the following link, thank you, https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=78GGHGLK5ZXAE
Видео New research game changer канала Dr. John Campbell
https://opensafely.org
New secure analytics platform
Electronic health records in the NHS
Created to deliver urgent results during the COVID-19 emergency
Analyses across more than 24 million patients
Full pseudonymised primary care NHS records
More to follow shortly
Open for security review
Scientific review
Secure environments
Trusted analysts
Large scale computation
Near real-time
Analyses in just five weeks from project start.
More accuracy than any previous analyses by an order of magnitude
Big data
Primary care data
Sufficient statistical power
Associations with specific medications and medical conditions
Early during the pandemic
Save lives by modifying patient, clinician, and population behaviour
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Lancet, 5th November, MRC
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30378-7/fulltext
Hydroxychloroquine
Pre¬exposure (as opposed to post¬exposure) prophylactic
Inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro
No evidence of reduced mortality when treating patients with COVID-19
Methods
Observational
Population-based cohort study
Approximately 40% of the general population in England
Association between ongoing use before COVID-19
Compared with non-users of hydroxychloroquine
Risk of COVID-19 mortality
People with rheumatoid arthritis or systemic lupus erythematosus
n = 194, 637 with rheumatoid arthritis or systemic lupus erythematosus
n = 30, 569 received two or more prescriptions of hydroxychloroquine
March 1 and July 13, 2020
547 deaths
Users (n= 30,569)
70 deaths
IFR = 0.23%
Non – users (n = 164,068)
IFR = 0.22%
An absolute difference of 0·008%
Accounting for age, sex, ethnicity, use of other immunosuppressive drugs, and geographical
region
No association with COVID-19 mortality was observed
If you would like to donate to this educational project, please use the following link, thank you, https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=78GGHGLK5ZXAE
Видео New research game changer канала Dr. John Campbell
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Long term immunity, looking goodSecond vaccine with high immunityWinter Vitamin D UpdateVaccine, looking very goodHands, face, space AND VentilateHigh US positive test ratesSecond Wave UpdateUK R value is now below 1COVID-19 and ZincCoronavirus Update 116: Pfizer COVID 19 Vaccine Explained (Biontech)Pandemic learning from JapanFormer FBI Agent Explains How to Read Body Language | Tradecraft | WIREDUS hospitalisations and mask wearingThe next COVID year and vaccine functionProstate ProblemsThe Epidemic of Fake DiseaseWho Gets Long Covid, and Why? | Huge Findings From New StudyHow COVID Kills Some People But Not Others - I'm a Lung Doctor (MEDICAL TRUTH) | CoronavirusPresident Trump's medications in detailUS and UK, mutations and vitamin D